Drug Trial Radar · NCT06192108
A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin
Last checked: Nov 20, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
962
Actual
Start
Jan 10, 2024
Primary completion
Sep 26, 2025
Study completion Sep 26, 2025
Sponsor
- Lead sponsor
- Eli Lilly and CompanyEli Lilly (LLY)
- Sponsor type
- Industry
- First posted
- Jan 5, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main purpose of this study is to assess the safety and efficacy of orforglipron compared with dapagliflozin in improving blood sugar control in participants with type 2 diabetes (T2D) with inadequate glycemic control using metformin. The study will last approximately 46 weeks.
Conditions
- Type 2 Diabetes
Interventions
OrforglipronDrug
Administered orally
DapagliflozinDrug
Administered orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in HbA1c [Noninferiority Analysis]Time frame: Baseline, Week 40
Locations
74 sites in 6 countries. Site status is shown where the registry gives one.
Alliance Research Institute - Canoga Park
Canoga Park, California
Ark Clinical Research
Long Beach, California
Collaborative Neuroscience Research, LLC
Los Alamitos, California
Wolverine Clinical Trials
Santa Ana, California
CMR of Greater New Haven, LLC
Hamden, Connecticut
Institute of Endocrinology Diabetes, Health & Hormone
Stockbridge, Georgia
Elite Clinical Trials
Rexburg, Idaho
Accellacare - DuPage
Lombard, Illinois
Tandem Clinical Research
Marrero, Louisiana
St. Vincent Healthcare
Billings, Montana
Albuquerque Clinical Trials, Inc.
Albuquerque, New Mexico
Accellacare - Winston-Salem
Winston-Salem, North Carolina
Alliance for Multispecialty Research, LLC
Norman, Oklahoma
Essential Medical Research
Tulsa, Oklahoma
Accellacare - Mt Pleasant
Mt. Pleasant, South Carolina
Accellacare, US Inc., d/b/a Accellacare of Knoxville
Jefferson City, Tennessee
Velocity Clinical Research, Dallas
Dallas, Texas
Juno Research
Houston, Texas
Consano Clinical Research, LLC
Shavano Park, Texas
The Second People's Hospital of Hefei
Hefei, Anhui, China
The Fourth Affiliated Hospital of Harbin Medical University
Harbin, Heilongjiang, China
The First Affiliated Hospital of Nanyang Medical College
Nanyang, Henan, China
The Second Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China
Nanjing First Hospital
Nanjing, Jiangsu, China
The Second Affiliated Hospital of Nanjing Medical University
Nanjing, Jiangsu, China
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China
Affiliated Hospital of Jiangsu University
Zhenjiang, Jiangsu, China
Jinan Central Hospital
Jinan, Shandong, China
Shanghai Sixth People's Hospital
Shanghai, Shanghai Municipality, China
First Affiliated Hospital of Kunming Medical University
Kunming, Yunnan, China
The First Affiliated Hospital of Wenzhou Medical University
Wenzhou, Zhejiang, China
Diabetes Zentrum Wilhelmsburg
Hamburg, Germany
CRS Clinical Research Services Mannheim
Mannheim, Baden-Wurttemberg, Germany
Diabetologische Schwerpunktpraxis Dr. Staudenmeyer & Dr. Schiwietz
Lingen, Lower Saxony, Germany
Diabetes- und Stoffwechselpraxis Bochum
Bochum, North Rhine-Westphalia, Germany
Zentrum fur klinische Forschung - Köln
Cologne, North Rhine-Westphalia, Germany
InnoDiab Forschung Gmbh
Essen, North Rhine-Westphalia, Germany
Medizentrum Essen Borbeck
Essen, North Rhine-Westphalia, Germany
Institut für Diabetesforschung GmbH Münster
Münster, North Rhine-Westphalia, Germany
Praxis Dr. Veronika Wenzl-Bauer
Rehlingen, Saarland, Germany
Showing 40 of 74 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.